Parkinson Study Group Announces Nilotinib Not Promising for Benefit in Phase II Trial
December 05, 2019
December 05, 2019
CHICAGO, Illinois, Dec. 5 -- The Michael J. Fox Foundation for Parkinson's Research issued the following news release:
Northwestern University and the Parkinson Study Group announced that the Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for potential repurposing as a Parkinson's drug, was safe and tolerable in its trial population of 76 participants with moderate to advanced Parkinson' . . .
Northwestern University and the Parkinson Study Group announced that the Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for potential repurposing as a Parkinson's drug, was safe and tolerable in its trial population of 76 participants with moderate to advanced Parkinson' . . .